Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

RSS icon
cocaine heart failure HFrEF LVEF hospitalizations beta-blockers hypertension cardiology

How cocaine use affects outcomes for hospitalized heart failure patients

When cocaine users are hospitalized for heart failure, what should physicians expect? Are beta-blockers an effective treatment strategy? 

Renal denervation is associated with improved blood pressure (BP) control and a reduced risk of adverse cardiovascular outcomes, according to two late-breaking clinical trials presented at EuroPCR 2022 in Paris. Both clinical trials focused on three-year data related to Medtronic’s Symplicity Spyral Renal Denervation (RDN) System, which was designed to lower BP through the use of a curling catheter that ablates overactive nerves.

Renal denervation improves blood pressure control, lowers risk of adverse cardiovascular outcomes

Two late-breaking clinical trials at EuroPCR 2022 in Paris focused on the potential benefits of renal denervation.

Thumbnail

Arterial stiffness may predict type 2 diabetes risk better than high blood pressure

Researchers tracked data from more than 11,000 adult patients, sharing their findings in Hypertension.

The American College of Cardiology (ACC) annual meeting is the premier source for the latest cardiac science. #ACC22

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

FDA announces recall of hypertension medications due to potential cancer risk

The voluntary recall includes quinapril HCl/hydrochlorothiazide tablets sold by Pfizer and authorized generics of that same medication. 

Hypertension patients benefit from new intervention focused on education, motivation and text messages

Improving the way we communicate with ED patients about their blood pressure could make a significant long-term impact on their health. 

4 new medications and technologies that could transform cardiology in 2022

The FDA has already approved one of the medications, with a decision on another expected by the end of April. 

Displaying 49 - 56 of 83
Design by Adaptive Theme